GSK Announces Commitment to Improving Access to Vaccines With 5-year Price Freeze
Thursday, August 28, 2014
GlaxoSmithKline (GSK) has announced that it will freeze the prices of its vaccines for five years for developing countries that graduate from GAVI Alliance support. By committing to offer GAVI Alliance prices for vaccines against pneumonia, diarrhoea and cervical cancer, GSK will support developing country governments as they transition to financing the full cost of their local vaccination programmes.
Since its formation in 2000, the GAVI Alliance has helped to fund the immunisation of 440 million children in some of the world’s poorest countries. GSK is a long-standing partner of the Alliance and reserves its lowest prices for GAVI-eligible countries, which can be as low as one-tenth of prices in developed countries.
Speaking at a European Commission/GAVI Alliance event in Brussels, Sir Andrew Witty, CEO of GSK paid tribute to the GAVI Alliance leadership and its partners including governments, donors, charities and vaccine manufacturers which together have enabled millions of children in the world’s poorest countries to receive innovative, life-saving vaccines.
Source: Nigerian Bulletin (link opens in a new window)
- Health Care